Article · Wikipedia archive · Last revised Jun 12, 2026

Levophenacylmorphan

Levophenacylmorphan is a morphinan derivative that acts as an opioid agonist. It has potent analgesic effects and is around 10x more potent than morphine. Adverse effects associated with its use are those of the opioids as a whole, including pruritus, nausea, respiratory depression, euphoria and development of tolerance and dependence to its effects.

Last revised
Jun 12, 2026
Read time
≈ 1 min
Length
212 w
Citations
3
Source
Wikipedia ↗
Levophenacylmorphan
Clinical data
Other namesLevophenacylmorphan
ATC code
  • none
Legal status
Legal status
Identifiers
  • (−)-3-Hydroxy-N-phenacylmorphinan
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.030.168
Chemical and physical data
FormulaC24H27NO2
Molar mass361.485 g·mol−1
3D model (JSmol)
  • C1CC[C@@]23CCN([C@@H]([C@@H]2C1)CC4=C3C=C(C=C4)O)CC(=O)C5=CC=CC=C5
  • InChI=1S/C24H27NO2/c26-19-10-9-18-14-22-20-8-4-5-11-24(20,21(18)15-19)12-13-25(22)16-23(27)17-6-2-1-3-7-17/h1-3,6-7,9-10,15,20,22,26H,4-5,8,11-14,16H2/t20-,22+,24+/m0/s1 ☒N
  • Key:RCYBMSQOSGJZLO-BGWNEDDSSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Levophenacylmorphan is a morphinan derivative that acts as an opioid agonist. It has potent analgesic effects and is around 10x more potent than morphine.2 Adverse effects associated with its use are those of the opioids as a whole, including pruritus, nausea, respiratory depression, euphoria and development of tolerance and dependence to its effects.3

See also

See also

References

References

  1. Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
  2. May E, Eddy N (February 1959). "A New Potent Synthetic Analgesic". Communications. The Journal of Organic Chemistry. 24 (2): 294–5. doi:10.1021/jo01084a655.
  3. Fraser HF, Isbell H (January 1960). "Human pharmacology and addiction liabilities of phenazocine and levophenacylmorphan". Bulletin on Narcotics. 12 (2): 15–23.